Roche, the French National Agency for Research on AIDS and Viral Hepatitis, Baylor Research Institute and Inserm Transfert Establish Strategic Collaboration to Develop Therapeutic Vaccines for Chronic Infectious Diseases
NUTLEY, NJ; DALLAS, TX; PARIS, France – April 3, 2012 –– Today Roche, the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), Baylor Research Institute (BRI, the research arm of Baylor Health Care System in Dallas), and Inserm Transfert announced a long-term collaboration to develop therapeutic vaccines for chronic infections. The researchers will utilize a novel technology platform developed by Baylor Institute for Immunology Research (BIIR), a component of BRI, and ANRS and Inserm associated research units, to identify and produce therapeutic vaccines that target dendritic cells, a critical component of the mammalian immune system.
“This targeted approach may be useful in a variety of areas of medical need. Our goal is to identify new and unique antibody constructs that will target specific dendritic cell subpopulations to drive and mount an immune response,” said Jean-Jacques Garaud, Head of Pharma Research and Early Development at Roche.